Inhibition of tissue angiotensin converting enzyme activity prevents malignant hypertension in TGR(mREN2)27

Journal of Hypertension

Volumn 16, Issue 5, 1998, Pages 635-643

  Montgomery, Hugh E ^a,d   Kiernan, Linda A ^a   Whitworth, Caroline E ^b   Fleming, Stewart ^b   Unger, Thomas ^c   Gohlke, Peter ^c   Mullins, John J ^c   McEwan, Jean R ^a  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c UNIVERSITY OF KIEL   (Germany)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Malignant hypertension; Renin angiotensin system; Transgenic rats

Indexed keywords

DIPEPTIDYL CARBOXYPEPTIDASE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; RAMIPRIL;

ANGIOTENSIN BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL WALL; CONTROLLED STUDY; ENZYME ACTIVITY; ENZYME INHIBITION; FIBROMUSCULAR DYSPLASIA; HEART; HETEROZYGOTE; HYPERTENSION; KIDNEY; MALE; MALIGNANT HYPERTENSION; NECROSIS; NONHUMAN; PATHOGENESIS; PLETHYSMOGRAPHY; PRIORITY JOURNAL; RAT; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; RESISTANCE BLOOD VESSEL; SYSTOLIC BLOOD PRESSURE;

EID: 0031982055     PISSN: 02636352     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004872-199816050-00011     Document Type: Article

References (70)

1. Klemperer P, Otani S. Malignant nephrosclerosis. Arch Pathol 1931; 11:60-117.
2. Kincaid-Smith P, McMichael J, Murphy EA. The clinical course and pathology of hypertension with papilloedema (malignant hypertension). Q J Med 1958; 27:117-153.
3. Sanerkin NG. Vascular lesions of malignant essential hypertension. J Pathol 1971; 103:177-184.
4. Jones DB. Arterial and glomerular lesions associated with severe hypertension. Lab Invest 1974; 31:303-313.
5. Kincaid-Smith P. Renal pathology in malignant hypertension and the effects of treatment. Br J Clin Pharmacol 1982; 13:107-115.
6. Houston M. Pathophysiology, clinical aspects, and treatment of hypertensive crises. Prog Cardiovasc Dis 1989; 22:99-148.
7. Patel R, Ansari A, Grim C. Prognosis and predisposing factors for essential hypertension in predominantly black patients. Am J Cardiol 1990; 66:868-869.
8. Beilin LJ, Goldby FS, Mohring J. High arterial pressure versus humoral factors in the pathogenesis of the vascular lesions of malignant hypertension. Clin Sci Mol Med 1977; 52:111-117.
9. Laragh JH, Januszewicz V, Deming QB, Kelly WG, Lieberman S. Aldosterone secretion and primary and malignant hypertension. J Clin Invest 1960; 39:1091-1106.
10. Buhler FR, Laragh JH, Baer L, Vaughan ED, Brunner HR. Propranolol inhibition of renin secretion: a specific approach to diagnosis and treatment of renin-dependent hypertensive diseases. N Engl J Med 1972; 287:1209-1214.
11. Giese J. The renin-angiotensin system and the pathogenesis of vascular disease in malignant hypertension. Clin Sci Mol Med 1976; 51:19s-21s.
12. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, et al. Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensive rats. Hypertension 1994; 24:195-204.
13. Gavras H, Brunner HR, Laragh JH, Vaughan ED, Koss M, Cote U, et al. Malignant hypertension resulting from deoxycorticosterone acetate and salt excess. Circ Res 1975; 36:300-309.
14. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, et al. Renal injury from angiotensin II-mediated hypertension. Hypertension 1992; 19:464-474.
15. Lohmeier TE, Tillman LJ, Carroll RG, Brown AJ, Guyton AC. Malignant hypertensive crisis induced by chronic intrarenal norepinephrine infusion. Hypertension 1984; 6 (suppl 1):I177-I182.
16. Whitworth CE, Fleming S, Kotelevtsev Y, Manson L, Brooker GA, Cumming AD, et al. A genetic model of malignant phase hypertension in rats. Kidney Int 1995; 47:529-535.
17. Mullins JJ, Peters J, Ganten D. Fulminant hypertension in transgenic rats harbouring the mouse Ren-2 gene. Nature 1990; 344:541-544.
18. Bachmann S, Peters J, Engler E, Ganten D, Mullins J. Transgenic rats carrying the mouse renin gene - morphological characterization of a low-renin hypertension model. Kidney Int 1992; 41:24-36.
19. Barrett GL, Mullins JJ. Studies on blood pressure regulation in hypertensive Ren-2 transgenic rats. Kidney Int 1992; 41 (suppl 37):S125-S128.
20. Lo M, Medeiros IA, Mullins JJ, Ganten D, Barres C, Cerutti C, et al. High blood pressure maintenance in transgenic mRen-2 vs. Lyon genetically hypertensive rats. Am J Physiol 1993; 265:R180-R186.
21. Moriguchi A, Brosnihan K, Kumagai H, Ganten D, Ferrario CM. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am J Physiol 1994; 266:R1273-R1279.
22. Hirth-Dietrich C, Stasch J-P, Ganten D, Luft FC. Renal effects of captopril and nitrendipine in transgenic rats with an extra renin gene. Hypertension 1994; 23:626-631.
23. Tokita Y, Franco-Saenz R, Mulrow PJ, Ganten D. Effect of nephrectomy and adrenalectomy on the renin-angiotensin system of transgenic rats TGR(mRen2)27. Endocrinology 1994; 134:253-257.
24. Veniant M, Whitworth CE, Menard J, Sharp MGF, Gonzales M-F, Bruneval P, et al. Developmental studies demonstrate age-dependent elevation of renin activity in TGR(mRen2)27 rats. Am J Hypertens 1995; 8:1167-1176.
25. Unger T, Schull B, Rascher W, Lang RE, Ganten D. Selective activation of the converting enzyme inhibitor MK421 and comparison of its active diacid form with captopril in different tissues of the rat. Biochem Pharmacol 1982; 31:3063-3070.
26. Pickering G. Reversibility of malignant hypertension. Lancet 1971; i:413-418.
27. Mohring J, Mohring B, Naumann H-J, Philippi A, Homsy E, Orth H. Salt and water balance and renin activity in renal hypertension of rats. Am J Physiol 1975; 228:1847-1855.
28. McAllister R, Van Way C, Dayani K, Anderson W, Temple E, Michelakis A, et al. Malignant hypertension: effect of therapy on renin and aldosterone. Circ Res 1971; 28 (suppl II):160-173.
29. Gardiner D, Lindop G. Peripolar cells, granulated glomerular epithelial cells, and their relationship to the juxtaglomerular apparatus in malignant hypertension. J Pathol 1992; 167:59-64.
30. Masson GMC, Mikasa A, Yasuda H. Experimental vascular disease elicited by aldosterone and renin. Endocrinology 1961; 71:505-512.
31. Masson GMC, Kashii C, Matsunaga M, Page IH. Hypertensive vascular disease produced by homologous renin. Science 1964; ?:178-180.
32. Saragoca MA, Homsi E, Ribeiro AB, Ferreira Filho SR, Ramos OL. Hemodynamic mechanism of blood pressure response to captopril in human malignant hypertension. Hypertension 1983; 5 (suppl I): I53-I58.
33. Orth H, Ritz E. Sodium depletion in accelerated hypertension. N Engl J Med 1975; 292:1133.
34. Click RL, Joyner WL, Gilmore JP. Reactivity of glomerular afferent and efferent arterioles in renal hypertension. Kidney Int 1979; 15: 109-115.
35. Goldby FS, Beilin LJ. How an acute rise in arterial pressure damages arterioles. Electron microscopic changes during angiotensin infusion. Cardiovasc Res 1972; 6:569-584.
36. Gavras H, Brown JJ, Lever AF, Macadam RF. Acute renal failure, tubular necrosis, and myocardial infarction induced in the rabbit by intravenous angiotensin II. Lancet 1971; ii:19-22.
37. Bunag RD, Riley E. Simultaneous measurements in awake rats of drug-induced changes in carotid and tail-cuff systolic pressures. J Appl Physiol 1974; 36:621-624.
38. Bunag RD. Validation in awake rats of a tail-cuff method for measuring systolic pressure. J Appl Physiol 1973; 34:279-282.
39. Pfeffer JM, Reffer MA, Frohlich ED. Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanaesthetized normotensive and spontaneously hypertensive rats. J Lab Clin Med 1971; 78:957-962.
40. Kuwahara M, Sugano S, Yayou K, Tsubone H, Kobayashi H. Evaluation of a new tail-cuff method for blood-pressure measurements in rats with special reference to the effects of ambient temperature. Jikken Dobutsu 1991; 40:331-336.
41. Yamakoshi KI, Shimazu H, Togawa T. Indirect measurement of instantaneous arterial blood pressure in the rat. Am J Physiol 1979; 237:H632-H637.
42. Ikeda K, Nara Y, Yamori Y. Indirect systolic and mean blood pressure determination by a new tail cuff method in spontaneously hypertensive rats. Lab Anim 1991; 25:26-29.
43. Higashino H, Simeonova K, Lambev I, Markov M, Suzuki A. Proper measurement of blood pressure and heart rate in SHRSP and WKY by an indirect volume-oscillometric method. Clin Exp Pharmacol Physiol 1995; 1 (suppl):S292-S293.
44. Bunag RD, Butterfield J. Tail-cuff blood pressure measurement without external preheating in awake rats. Hypertension 1982; 4:898-903.
45. Sakamaki T, Tajima Y, Ichikawa S, Murata K. Measurement of mean arterial pressure in rats by a tail-cuff method with sensitive photoelectric sensors. Jikken Dobutsu 1987; 36:409-414.
46. Christensen KL, Mulvany MJ, Jespersen LT. Can mean arterial pressure be estimated from measurements of systolic and diastolic blood pressure, and vice versa? J Hypertens 1990; 8:321-326.
47. Lovenberg W. Techniques for the measurement of blood pressure. J Hypertens 1987; 9 (suppl I):I5-I6.
48. Schunkert H, Inglefinger JR, Hirsch AT, Pinto Y, Remme WJ, Jacob H, et al. Feedback regulation of angiotensin-converting enzyme activity and mRNA levels by angiotensin II. Circ Res 1993; 72:312-318.
49. Unger T, Schull B, Hubner D, Yukimura T, Lang RE, Rascher W, et al. Plasma-converting enzyme activity does not reflect effectiveness of oral treatment with captopril. Eur J Pharmacol 1981; 72:255-259.
50. Ulm EH, Vassil TC. Total serum angiotensin converting enzyme activity in rats and dogs after enalapril maleate (MK-421). Life Sci 1982; 30:1225-1230.
51. Fornes P, Richer C, Vacher E, Bruneval P, Giudicelli J-F. Losartan's protective effects in stroke-prone spontaneously hypertensive rats persist durably after treatment withdrawal. J Cardiovasc Pharm 1993; 22:305-313.
52. Sinclair RA, Antonovych TT. Renal proliferative arteriopathies and associated glomerular changes. A light and electron microscopic study. Human Path 1976; 7:565-588.
53. Ishidoya S, Morrissey J, McCracken R, Klahr S. Delayed treatment with enalapril halts tubulointerstitial fibrosis in rats with obstructive nephropathy. Kidney Int 1996; 46:1110-1119.
54. Tan L-B, Jalil JE, Pick R, Janicki JS, Weber KT. Cardiac myocyte necrosis induced by angiotensin II. Circ Res 1991; 69:1185-1195.
55. Kincaid-Smith P. Management of severe hypertension. Am J Cardiol 1973; 32:575-581.
56. Steinhausen M, Kucherer H, Parekh N, Weis S, Wiegman DL, Wilhelm KR. Angiotensin II control of the renal microcirculation: effect of blockade by salarasin. Kidney Int 1986; 30:56-61.
57. Geisterfer AAT, Peach MJ, Owens GK. Angiotensin II induces hypertrophy, not hyperplasia, of cultured rat aortic smooth muscle cells. Circ Res 1988; 62:749-756.
58. Heagerty AM. Angiotensin II: vasoconstrictor or growth factor? J Cardiovasc Pharmacol 1991; 18 (suppl 2):S14-S19.
59. Fabris B, Jackson B, Johnston CI. Salt blocks the renal benefits of ramipril in diabetic hypertensive rats. Hypertension 1991; 17:497-503.
60. Nishida N, Ogura T, Yamauchi T, Hosoya M, Ota Z. Treatment with cilazapril, angiotensin-converting enzyme inhibitor, changes the affinity of arginine vasopressin receptor in the kidney of the spontaneously hypertensive rat. Res Commun Chem Pathol Pharmacol 1994; 84:143-152.
61. Auch-Schwelk W, Kuchenbuch C, Walther B, Bossaller C, Friedel N, Graf K, et al. Local regulation of vascular tone by bradykinin and angiotensin converting enzyme inhibitors. Eur Heart J 1993; 14 (suppl I):154-160.
62. Farhy RD, Ho K-L, Carretero DA, Scicli AG. Kinins mediate the antiproliferative effect of ramipril in rat carotid artery. Biochem Biophys Res Commun 1992; 182:283-288.
63. Linz W, Scholkens BA. A specific B2-bradykinin receptor antagonist HOE 140 abolishes the antihypertrophic effect of ramipril. Br J Pharmacol 1992; 105:771-772.
64. Seyedi N, Xu X, Nasjletti A, Hintze TH. Coronary kinin generation mediates nitric oxide release after angiotensin receptor stimulation. Hypertension 1995; 26:164-170.
65. Ishimitsu T, Tobian L. High potassium diets reduce endothelial permeability in stroke-prone spontaneously hypertensive rats. Clin Exp Pharmacol Physiol 1996; 23:241-245.
66. Ishimitsu T, Tobian L, Uehara Y, Sugimoto K, Lange JM. High potassium diets reduce macrophage adherence to the vascular wall in stroke-prone spontaneously hypertensive rats. J Vasc Res 1995; 32:406-412.
67. Tobian L, Sugimoto T, Johnson MA, Hanlon S. High K diets protect against hypertensive intimai lesions and endothelial injury in arteries of stroke-prone hypertensive rats. Trans Assoc Am Physicians 1987; 100:300-304.
68. Sugimoto K, Tobin L, Ishimitsu T, Lange JM. High potassium diets greatly increase growth-inhibiting agents in aortas of hypertensive rats. Hypertension 1992; 19:749-752.
69. Ganguli M, Tobian L, Sugimoto T. Deleterious effects of high magnesium diets and beneficial effects of high potassium diets in hypertensive strokeprone rats. Magnes Res 1990; 3:255-261.
70. Tobian L, Lange JM, Johnson MA, MacNeill DA, Wilke TJ, Ulm KM, et al. High-K diets reduce brain haemorrhage and infarcts, death rate and mesenteric arteriolar hypertrophy in stroke-prone spontaneously hypertensive rats. J Hypertens 1986; 4 (suppl):S205-S207.